medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-24-27-30medalphabet-2832Research ArticleСтатьиКомбинированная гормональная контрацепция: причины отказа и применение у женщин групп высокого рискаCombined hormonal contraception: reasons for refusal and use in high-risk womenhttps://orcid.org/0000-0001-9481-8812КравченкоЕ. Н.KravchenkoE. N.

Кравченко Елена Николаевна, д. м. н., проф., профессор кафедры акушерства и гинекологии

г. Омск

Kravchenko Elena N., DM Sci (habil.), professor, professor of the Department of Obstetrics and Gynecology of the 1st Federal State Budgetary Educational Institution of Higher Education

Omsk

kravchenko.en@mail.ruФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияOmsk State Medical UniversityRussian Federation202220112022024Современная гинекология (2)2730Copyright © Кравченко Е.Н., 20222022Кравченко Е.Н.Kravchenko E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2832Цель

Цель. В статье рассматриваются возможность использования комбинированной гормональной контрацепции, причины отказа и применение у женщин групп высокого риска.

Методы

Методы. Проведен обзор данных за 5 лет, проанализированы факторы, которые привели к отказу использования этого вида контрацепции. Собрана информация о руководящих принципах действий у пациентов с высоким риском появления побочных эффектов, использующих комбинированную гормональную контрацепцию.

Выводы

Выводы. Страх женщин перед нежелательными явлениями и формированием проблем со здоровьем является одной из основных причин отказа от применения контрацептивов или полного прекращения их использования. Будущие исследования должны изучить предвзятость пользователей к гормональной контрацепции для лучшего понимания контроля над рождаемостью, улучшения соответствия потребностям и ожиданиям женщин и мужчин сегодня.

Purpose

Purpose: the article discusses the possibility of using combined hormonal contraception, the reasons for refusal and the use in women of high-risk groups.

Methods

Methods: a review of data for 5 years was carried out, the factors that led to the refusal to use this type of contraception were analyzed. Information has been collected on the guidelines for action in patients with a high risk of side effects using combined hormonal contraception.

Conclusions

Conclusions: women’s fear of adverse events, the formation of health problems, are one of the main reasons for refusing to use contraceptives or completely stopping their use. Future research should explore user bias towards hormonal contraception for a better understanding of birth control, better matching the needs and expectations of women and men today.

комбинированная гормональная контрацепцияпричины отказаприменение у женщин групп высокого рискаcombined hormonal contraceptionreasons for refusaluse in high-risk womenReferencesAbbe CR, Page ST, Thirumalai A. Male Contraception. Yale J Biol Med. 2020 Sep 30;93(4):603–613. PMID: 33005125; PMCID: PMC 7513428.Abbe CR, Page ST, Thirumalai A. Male Contraception. Yale J Biol Med. 2020 Sep 30;93(4):603–613. PMID: 33005125; PMCID: PMC 7513428.Canadian Contraception Consensus (Part 2 of 4). Journal of obstetrics and gynaecology Canada: JOGC = Journal d’obstetrique et gynecologie du Canada: JOGC. Vol. 37,11 (2015): 1033–9. doi: 10.1016/s1701–2163(16)30054-8Canadian Contraception Consensus (Part 2 of 4). Journal of obstetrics and gynaecology Canada: JOGC = Journal d’obstetrique et gynecologie du Canada: JOGC. Vol. 37,11 (2015): 1033–9. doi: 10.1016/s1701–2163(16)30054-8Regidor Pedro-Antonio. Clinical relevance in present day hormonal contraception. Hormone molecular biology and clinical investigation. Vol. 37,1 10.1515/hmbci-2018–0030. 26 Oct. 2018. doi: 10.1515/hmbci-2018–0030Regidor Pedro-Antonio. Clinical relevance in present day hormonal contraception. Hormone molecular biology and clinical investigation. Vol. 37,1 10.1515/hmbci-2018–0030. 26 Oct. 2018. doi: 10.1515/hmbci-2018–0030Teal S, Edelman A. Contraception Selection, Effectiveness, and Adverse Effects: A Review. JAMA. 2021 Dec 28;326(24):2507–2518. doi: 10.1001/jama.2021.21392. PMID: 34962522.Teal S, Edelman A. Contraception Selection, Effectiveness, and Adverse Effects: A Review. JAMA. 2021 Dec 28;326(24):2507–2518. doi: 10.1001/jama.2021.21392. PMID: 34962522.Brown EJ, Deshmukh P, Antell K. Contraception Update: Oral Contraception. FP Essent. 2017 Nov;462:11–19. PMID: 29172411.Brown EJ, Deshmukh P, Antell K. Contraception Update: Oral Contraception. FP Essent. 2017 Nov;462:11–19. PMID: 29172411.Le Guen, Mireille et al. Reasons for rejecting hormonal contraception in Western countries: A systematic review. Social science & medicine (1982). Vol. 284 (2021): 114247. doi: 10.1016/j.socscimed.2021.114247Le Guen, Mireille et al. Reasons for rejecting hormonal contraception in Western countries: A systematic review. Social science & medicine (1982). Vol. 284 (2021): 114247. doi: 10.1016/j.socscimed.2021.114247Regidor Pedro-Antonio. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. Vol. 9,77 34628–34638. 2 Oct. 2018, doi: 10.18632/oncotarget.26015Regidor Pedro-Antonio. The clinical relevance of progestogens in hormonal contraception: Present status and future developments. Oncotarget. Vol. 9,77 34628–34638. 2 Oct. 2018, doi: 10.18632/oncotarget.26015Marsden Jo. Hormonal contraception and breast cancer, what more do we need to know? Post reproductive health. Vol. 23,3 (2017): 116–127. doi: 10.1177/2053369117715370Marsden Jo. Hormonal contraception and breast cancer, what more do we need to know? Post reproductive health. Vol. 23,3 (2017): 116–127. doi: 10.1177/2053369117715370Sales Vieira C, Celis C, Galán G, Hernández L, Díaz I, López J. Drospirenone: a Latin American perspective for oestrogen-free oral contraception. Eur J Contracept Reprod Health Care. 2021 Feb;26(1):73–78. doi: 10.1080/13625187.2020.1837364. Epub 2020 Nov 6. PMID: 33155847.Sales Vieira C, Celis C, Galán G, Hernández L, Díaz I, López J. Drospirenone: a Latin American perspective for oestrogen-free oral contraception. Eur J Contracept Reprod Health Care. 2021 Feb;26(1):73–78. doi: 10.1080/13625187.2020.1837364. Epub 2020 Nov 6. PMID: 33155847.Systematic Review of Hormonal Contraception and Risk of Venous Thrombosis. The Linacre quarterly. Vol. 85,4 (2018): 470–477. doi: 10.1177/0024363918816683Systematic Review of Hormonal Contraception and Risk of Venous Thrombosis. The Linacre quarterly. Vol. 85,4 (2018): 470–477. doi: 10.1177/0024363918816683Lete Iñaki. Combined hormonal contraception and COVID-19. The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception. Vol. 26,2 (2021): 128–131. doi: 10.1080/13625187.2020.1867845Lete Iñaki. Combined hormonal contraception and COVID-19. The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception. Vol. 26,2 (2021): 128–131. doi: 10.1080/13625187.2020.1867845Caruso Salvatore et al. Sexual activity and contraceptive use during social distancing and self-isolation in the COVID-19 pandemic. The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception. Vol. 25,6 (2020): 445–448. doi: 10.1080/13625187.2020.1830965Caruso Salvatore et al. Sexual activity and contraceptive use during social distancing and self-isolation in the COVID-19 pandemic. The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception. Vol. 25,6 (2020): 445–448. doi: 10.1080/13625187.2020.1830965Voedisch AJ, Hindiyeh N. Combined hormonal contraception and migraine: are we being too strict? Curr Opin Obstet Gynecol. 2019 Dec;31(6):452–458. doi: 10.1097/GCO.0000000000000586. PMID: 31573998.Voedisch AJ, Hindiyeh N. Combined hormonal contraception and migraine: are we being too strict? Curr Opin Obstet Gynecol. 2019 Dec;31(6):452–458. doi: 10.1097/GCO.0000000000000586. PMID: 31573998.McCloskey LR, Wisner KL, Cattan MK, Betcher HK, Stika CS, Kiley JW. Contraception for Women With Psychiatric Disorders. Am J Psychiatry. 2021 Mar 1;178(3):247–255. doi: 10.1176/appi.ajp.2020.20020154. Epub 2020 Nov 10. PMID: 33167674.McCloskey LR, Wisner KL, Cattan MK, Betcher HK, Stika CS, Kiley JW. Contraception for Women With Psychiatric Disorders. Am J Psychiatry. 2021 Mar 1;178(3):247–255. doi: 10.1176/appi.ajp.2020.20020154. Epub 2020 Nov 10. PMID: 33167674.Fruzzetti Franca and Tiziana Fidecicchi. Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice. Clinical drug investigation. Vol. 40,12 (2020): 1097–1106. doi: 10.1007/s40261-020-00966-8Fruzzetti Franca and Tiziana Fidecicchi. Hormonal Contraception and Depression: Updated Evidence and Implications in Clinical Practice. Clinical drug investigation. Vol. 40,12 (2020): 1097–1106. doi: 10.1007/s40261-020-00966-8Both Stephanie et al. Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM). The Journal of sexual medicine. Vol. 16,11 (2019): 1681–1695. doi: 10.1016/j.jsxm.2019.08.005Both Stephanie et al. Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM). The Journal of sexual medicine. Vol. 16,11 (2019): 1681–1695. doi: 10.1016/j.jsxm.2019.08.005Girum T, Wasie A. Return of fertility after discontinuation of contraception: a systematic review and meta-analysis. Contracept Reprod Med. 2018 Jul 23;3:9. doi: 10.1186/s40834–018–0064-y. PMID: 30062044; PMCID: PMC 6055351.Girum T, Wasie A. Return of fertility after discontinuation of contraception: a systematic review and meta-analysis. Contracept Reprod Med. 2018 Jul 23;3:9. doi: 10.1186/s40834–018–0064-y. PMID: 30062044; PMCID: PMC 6055351.Grandi Giovanni et al. Hormonal contraception in women with endometriosis: a systematic review. The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception. Vol. 24,1 (2019): 61–70. doi: 10.1080/13625187.2018.1550576Grandi Giovanni et al. Hormonal contraception in women with endometriosis: a systematic review. The European journal of contraception & reproductive health care: the official journal of the European Society of Contraception. Vol. 24,1 (2019): 61–70. doi: 10.1080/13625187.2018.1550576Jensen, Jeffrey T et al. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertility and sterility. Vol. 110,1 (2018): 137–152.e1. Doi: 10.1016/j.fertnstert.2018.03.012Jensen, Jeffrey T et al. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertility and sterility. Vol. 110,1 (2018): 137–152.e1. Doi: 10.1016/j.fertnstert.2018.03.012

The authors declare that there are no conflicts of interest present.